SGB Inc

SGB Inc., operating as VentiRx, is a clinical stage biopharmaceutical company headquartered in Summit, New Jersey. Employing 8 individuals, VentiRx generates approximately $20 million in annual revenue. VentiRx focuses on developing and commercializing innovative Toll-like Receptor 8 (TLR8) immunotherapies. Their therapeutic approach targets a variety of diseases, including cancer, respiratory illnesses, and inflammatory conditions. VentiRx's extensive clinical pipeline includes VTX-2337, a small molecule TLR8 agonist currently undergoing multiple clinical trials. These trials explore the efficacy of VTX-2337 in combination with chemotherapy and monoclonal antibodies for cancer treatment. A significant milestone for VentiRx was entering into a worldwide strategic collaboration with Celgene Corporation for the development of VTX-2337. This partnership aims to accelerate the clinical advancement and potential commercialization of this promising cancer treatment. For further information, please visit VentiRx's website at ventirx.com.